484 related articles for article (PubMed ID: 19550387)
1. Abnormal growth in noonan syndrome: the challenge of optimal therapy.
Savage MO; Padidela R; Kirk JM; Malaquias AC; Jorge AA
Pediatr Endocrinol Rev; 2009 Jun; 6 Suppl 4():523-8. PubMed ID: 19550387
[TBL] [Abstract][Full Text] [Related]
2. Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.
Padidela R; Camacho-Hübner C; Attie KM; Savage MO
Horm Res; 2008; 70(3):129-36. PubMed ID: 18663312
[TBL] [Abstract][Full Text] [Related]
3. Response to growth hormone in short children with Noonan syndrome: correlation to genotype.
Binder G
Horm Res; 2009 Dec; 72 Suppl 2():52-6. PubMed ID: 20029239
[TBL] [Abstract][Full Text] [Related]
4. GH therapy in Noonan syndrome: Review of final height data.
Dahlgren J
Horm Res; 2009 Dec; 72 Suppl 2():46-8. PubMed ID: 20029237
[TBL] [Abstract][Full Text] [Related]
5. Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome.
Lee ST; Ki CS; Lee HJ
Clin Genet; 2007 Aug; 72(2):150-5. PubMed ID: 17661820
[TBL] [Abstract][Full Text] [Related]
6. Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
Binder G
Horm Res; 2009 Apr; 71 Suppl 2():64-70. PubMed ID: 19407499
[TBL] [Abstract][Full Text] [Related]
7. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome.
Binder G; Neuer K; Ranke MB; Wittekindt NE
J Clin Endocrinol Metab; 2005 Sep; 90(9):5377-81. PubMed ID: 15985475
[TBL] [Abstract][Full Text] [Related]
8. Genetic and pathogenetic aspects of Noonan syndrome and related disorders.
Zenker M
Horm Res; 2009 Dec; 72 Suppl 2():57-63. PubMed ID: 20029240
[TBL] [Abstract][Full Text] [Related]
9. Noonan syndrome: growth to growth hormone - the experience of observational studies.
Ranke MB
Horm Res; 2009 Dec; 72 Suppl 2():36-40. PubMed ID: 20029235
[TBL] [Abstract][Full Text] [Related]
10. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway.
Jorge AA; Malaquias AC; Arnhold IJ; Mendonca BB
Horm Res; 2009; 71(4):185-93. PubMed ID: 19258709
[TBL] [Abstract][Full Text] [Related]
11. [Phenotype variability in Noonan syndrome patients with and without PTPN11 mutation].
Ferreira LV; Souza SA; Montenegro LR; Arnhold IJ; Pasqualini T; Heinrich JJ; Keselman AC; Mendonça BB; Jorge AA
Arq Bras Endocrinol Metabol; 2007 Apr; 51(3):450-6. PubMed ID: 17546245
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the PTPN11 gene in idiopathic short stature children and Noonan syndrome patients.
Ferreira LV; Souza SC; Montenegro LR; Malaquias AC; Arnhold IJ; Mendonca BB; Jorge AA
Clin Endocrinol (Oxf); 2008 Sep; 69(3):426-31. PubMed ID: 18331608
[TBL] [Abstract][Full Text] [Related]
13. Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndrome.
Blum WF; Cao D; Hesse V; Fricke-Otto S; Ross JL; Jones C; Quigley CA; Binder G
Horm Res; 2009; 71(3):167-72. PubMed ID: 19188742
[TBL] [Abstract][Full Text] [Related]
14. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.
Noordam C; Peer PG; Francois I; De Schepper J; van den Burgt I; Otten BJ
Eur J Endocrinol; 2008 Sep; 159(3):203-8. PubMed ID: 18562489
[TBL] [Abstract][Full Text] [Related]
15. [Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway].
Molven A; Søvik O; von der Lippe C; Steine SJ; Njølstad PR; Houge G; Prescott TE
Tidsskr Nor Laegeforen; 2009 Nov; 129(22):2358-61. PubMed ID: 19935936
[TBL] [Abstract][Full Text] [Related]
16. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y; Niihori T; Narumi Y; Kure S; Matsubara Y
Hum Mutat; 2008 Aug; 29(8):992-1006. PubMed ID: 18470943
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of mutations in Noonan syndrome and their correlation with phenotypes.
Lee BH; Kim JM; Jin HY; Kim GH; Choi JH; Yoo HW
J Pediatr; 2011 Dec; 159(6):1029-35. PubMed ID: 21784453
[TBL] [Abstract][Full Text] [Related]
18. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.
Ferreira LV; Souza SA; Arnhold IJ; Mendonca BB; Jorge AA
J Clin Endocrinol Metab; 2005 Sep; 90(9):5156-60. PubMed ID: 15956085
[TBL] [Abstract][Full Text] [Related]
19. [The Noonan syndrome from a pediatric perspective].
Noordam C; Thoonen G; van der Burgt CJ
Ned Tijdschr Geneeskd; 2003 Apr; 147(14):644-8. PubMed ID: 12712646
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone and the heart in Noonan syndrome.
Noordam C
Horm Res; 2009 Dec; 72 Suppl 2():49-51. PubMed ID: 20029238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
